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INTRODUCTION 
Liver cirrhosis is associated with a wide range of cardiovascular 
abnormalities. This was first described by Kowalski and Abelmann who 
noted a higher resting cardiac output and decreased systemic vascular 
resistance in patients with cirrhosis1, 2. However, despite the hyperdynamic 
circulation, impaired ventricular contractility in response to stimuli was 
described in cirrhotic patients3-7. These abnormalities were initially thought 
to be a manifestation of latent alcoholic cardiomyopathy. But in the mid-
1980s, studies in nonalcoholic patients and in experimental animal models 
showed a similar pattern of blunted cardiac contractile responsiveness8-10. 
Thus these cardiovascular changes are now termed ‘cirrhotic 
cardiomyopathy’11-14. 
The prevalence of cirrhotic cardiomyopathy remains unknown at 
present. Features include structural, histological, electrophysiological, 
systolic and diastolic dysfunction. Multiple factors are considered as 
responsible, including impaired beta-adrenergic receptor signal transduction, 
abnormal membrane biophysical characteristics, and increased activity of 
cardiodepressant systems mediated by cGMP15. 
Overt heart failure is not generally a feature of cirrhotic 
cardiomyopathy, because the associated marked vasodilatation 
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accompanying the hyperdynamic circulation significantly reduces 
ventricular afterload.  However, major stresses on the cardiovascular system 
such as liver transplantation, infections and insertion of transjugular 
intrahepatic portosystemic shunts (TIPS) can unmask the presence of 
cirrhotic cardiomyopathy and thereby convert latent to overt heart failure. 
Cirrhotic cardiomyopathy may also contribute to the pathogenesis of 
hepatorenal syndrome and circulatory failure in liver cirrhosis15. 
Diastolic dysfunction is present in the vast majority of patients with 
cirrhotic cardiomyopathy, and that simple echocardiographic indices such as 
the E/A ratio may detect diastolic dysfunction even at rest. This may 
therefore represent the best available screening test to diagnose cardiac 
dysfunction16. 
Due to the limited number of human studies, the management of 
cirrhotic cardiomyopathy remains largely empirical. Treatment of this 
condition is mainly supportive. Orthotropic liver transplantation appears to 
improve or normalize the condition, generally after a period of several 
months17. If overt heart failure develops in these patients, then the same 
general treatment principles of noncirrhotic congestive heart failure apply, 
including bed rest, salt restriction, oxygen, diuretics, and careful preload and 
afterload reduction 14. 
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LITERATURE REVIEW 
Cirrhosis is a gradually developing, chronic disease of the liver. It is 
the irreversible consequence and final stage of various chronic liver diseases 
of different etiology or the result of long-term exposure to various noxious 
agents. Aretaeus (2nd century AD) coined the term “skirros”, because he 
thought that inflammation of the liver led to its hardening (skirros). 
The first accurate report on cirrhosis was given by R.T.H. Laennec 
(1819). Because of the yellow colour of the liver (kirros), he coined the term 
cirrhosis. The extent of the morphological changes depends on the cause and 
stage of cirrhosis. Accordingly, there is a wide spectrum of morphological 
findings and clinical symptoms. The variations of this disease range from 
symptom-free conditions, noncharacteristic complaints and different 
laboratory findings through to life-threatening complications. 
 
Cirrhosis of liver can be classified either etiologically or 
morphologically. The etiological classification is based on the underlying 
cause which includes alcohol, hepatitis B and hepatitis C infections, 
metabolic disorders like Wilson disease, nonalcoholic fatty liver disease and 
also due to autoimmune hepatitis. When no cause is found it is called as 
cryptogenic cirrhosis. Morphological classification is based on the size of 
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the nodules. It could be micronodular if the nodules are less than 3 mm, 
macronodular if they are more than 3 mm and mixed type if both are found. 
The mixed type is the transition form from micronodular to macronodular 
cirrhosis. 
Cirrhosis of the liver is a disease found all over the world, affecting all 
races, age groups and both sexes. The incidence is about 240/million 
inhabitants/year. The increasing mortality rate runs parallel to regional 
alcohol consumption. This correlation between alcohol consumption and 
mortality as well as morbidity due to cirrhosis applies equally to men and 
women.  The slight decrease in mortality in some countries observed during 
the past 10 -15 years may be due to more effective prophylaxis and 
improved treatment options for complications. 
 
Hemodynamic changes in cirrhosis 
Portal hypertension is one of the salient features of cirrhosis.  
Cirrhosis of the liver accounts for approximately 90% of cases of portal 
hypertension. Portal hypertension is a common clinical syndrome defined by 
a pathologic increase of portal venous pressure. As a consequence, the 
gradient between portal pressure (PP) and inferior vena cava pressure (IVC) 
(portal pressure gradient, PPG) is increased above the upper normal value of 
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5 mm Hg. The importance of portal hypertensive syndrome is defined by the 
frequency and severity of its complications, including upper gastrointestinal 
bleeding from ruptured gastroesophageal varices, ascites, and hepatorenal 
Syndrome, which represent the leading causes of death and of liver 
transplantation in patients with cirrhosis. 
Portal hypertension is considered to be clinically significant (CSPH) 
when PPG, or its clinical equivalent hepatic venous pressure gradient 
(HVPG), exceeds 10 to 12 mm Hg, since this is the threshold for the clinical 
manifestations of portal hypertensive syndrome to appear. The vast majority 
of patients with cirrhosis develop CSPH along the course of the disease, and 
data from a recent multicentric study indicate that CSPH is already present 
at diagnosis in approximately 60% of histologically proven, well-
compensated cirrhosis case. 
 
Portal hypertension is related both to vascular resistance and to portal 
blood flow.  The fundamental hemodynamic abnormality is an increased 
resistance to portal flow. This may be mechanical due to the disturbed 
architecture and nodularity of cirrhosis or due to an obstructed portal vein. 
Other intra-hepatic factors such as collagenosis of the space of Disse, 
hepatocyte swelling and the resistance offered by portal-systemic collaterals 
 6
contribute. There is also a dynamic increase in intra-hepatic vascular 
resistance.  
Stellate (Ito) cells have contractile properties that can be modulated by 
vaso-active substances. These include nitric oxide (NO) which is 
vasodilatory and endothelin which is a vaso-constrictor. These may 
modulate intra-hepatic resistance and blood flow especially at a sinusoidal 
level.  
As the portal venous pressure is lowered by the development of 
collaterals deviating portal blood into systemic veins, portal hypertension is 
maintained by increasing portal flow in the portal system which becomes 
hyperdynamic. It is uncertain whether the hyperdynamic circulation is the 
cause or the consequence of the portal hypertension or both. It is related to 
the severity of liver failure. Cardiac output increases and there is generalized 
vasodilatation. Arterial blood pressure is normal or low.  
Splanchnic vasodilatation is probably the most important factor in 
maintaining the hyperdynamic circulation. Azygous blood flow is increased. 
Gastric mucosal blood flow rises. The increased portal flow raises the 
oesophageal variceal transmural pressure. The increased flow refers to total 
portal flow (hepatic and collaterals).The actual portal flow reaching the liver 
is, of course, reduced. The factors maintaining the hyperdynamic splanchnic 
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circulation are multiple. There seems to be interplay of vasodilators and 
vaso-constrictors. These might be formed by the hepatocyte, fail to be 
inactivated by it or be of gut origin and pass through intra-hepatic or extra-
hepatic venous shunts. 
Endotoxins and cytokines, largely formed in the gut, are important 
triggers. NO and endothelin-1 are synthesized by vascular endothelium in 
response to endotoxin. Prostacyclin is produced by portal vein endothelium 
and is a potent vasodilator. It may play a major role in the circulatory 
changes of portal hypertension due to chronic liver disease.  
Glucagon is vasodilatory after pharmacological doses but does not 
seem to be vaso-active at physiological doses. It is probably not a primary 
factor in the maintenance of the hyperkinetic circulation in established liver 
disease. 
Cardiac and vascular changes in cirrhosis 
The cardiovascular system in patients with cirrhosis or portal 
hypertension is abnormal. The circulation becomes hyperdynamic, 
characterized by increased cardiac output and decreased peripheral vascular 
resistance and arterial pressure. Moreover, despite the increased cardiac 
output at rest, with stressful stimuli such as hemorrhage, surgery or 
vasoactive drug administration, the ventricular response is blunted, a 
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condition known as cirrhotic cardiomyopathy. These cardiovascular 
abnormalities have been suggested to induce or aggravate several 
complications of cirrhosis such as renal salt and water retention, variceal 
bleeding, hepatopulmonary syndrome, and increased cardiovascular fragility 
under stress. Recent reviews have detailed the clinical aspects of 
hyperdynamic circulation18, 19 and cirrhotic cardiomyopathy20, 21, 22. 
 
HYPERDYNAMIC CIRCULATION 
Peripheral vasodilatation is central to hyperdynamic circulation and 
portal hypertension in cirrhosis. However, the factors directly initiating 
vasodilatation remain obscure. A hypothesis that has received much 
attention over the past three decades is the “humoral factor” theory. In 
cirrhosis, increased intrahepatic resistance induces portosystemic collateral 
formation, allowing gut-derived humoral substances to directly enter the 
systemic circulation without detoxification by the liver. The following gut-
derived or locally-produced humoral factors have been implicated as 
possible mediators of peripheral vasodilatation in cirrhosis or portal 
hypertension. 
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Endocannabinoids 
Endocannabinoids are lipid-like substances that act on two inhibitory 
G protein-coupled receptors, CB1 and CB2. The vasodilatory effect of 
endogenous cannabinoids in cirrhosis was first reported in 200123 
Anandamide, an endogenous cannabinoid or endocannabinoid, is increased 
in monocytes of cirrhotic rats 23,24, and its receptor CB1 is also upregulated 
in the vascular endothelium of patients with cirrhosis 23. Infusing monocytes 
isolated from cirrhotic rats into normal rats decreases the mean arterial 
pressure in the recipients. Furthermore, administering a CB1 receptor 
antagonist SR141716A to cirrhotic rats increases the total peripheral 
resistance23,24, both studies demonstrated that SR141716A significantly 
increases the reduced arterial pressure in cirrhosis, and blocks the 
hypotension induced by the infusion of isolated cirrhotic monocytes into 
normal rats23,24. Batkai and colleagues also found that SR141716A decreases 
mesenteric blood flow and portal venous pressure in cirrhotic rats 23. All of 
these data indicate that the vascular tone in cirrhosis is regulated by CB1 
receptors in both the splanchnic and systemic circulations. 
    Besides vasodilatation, anandamide rapidly and dose-dependently induces 
apoptosis in primary culture-activated and in vivo-activated hepatic stellate 
cells, with over 70% cell death after 4 h at 25 µmol/L25. This effect could 
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alter the hepatic sinusoidal microcirculation and enhance the development of 
portal hypertension that leads to hyperdynamic circulation. 
    How does cirrhosis leads to increased endocannabinoids? Varga and co-
workers found that bacterial endotoxin stimulates endocannabinoid 
production in cirrhosis 26. The up regulation of CB1 receptors in cirrhotic 
vascular endothelium and thus increased end-organ sensitivity may also 
enhance endocannabinoid vasodilator tone 23. 
  
Nitric oxide 
NO has been extensively studied. It is now clear that in cirrhosis, 
changes in NO activity affect different vascular beds in variable ways. In the 
liver microcirculation, endothelial-constitutive NO synthase (eNOS or 
NOS3) expression is decreased in a cirrhotic rat model 27. Simvastatin 
enhances hepatic nitric oxide production and decreases the hepatic vascular 
tone in patients with cirrhosis28. An NO donor29 or NOS3 gene 
transfection27, which compensates for the decreased hepatic NOS3 
expression, significantly lowers the increased portal pressure in cirrhosis. 
    In contrast, systemic NO production is increased in cirrhotic patients and 
animal models 30-32. Moreover, normalization of NO production in cirrhotic 
rats, by achieving normal concentrations of aortic cGMP with small doses of 
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the NOS inhibitor L-NAME, normalizes the decreased peripheral vascular 
resistance and the increased cardiac output 33. In vitro, an NO inhibitor 
reverses the hyporeactivity of blood vessels from cirrhotic rats to 
vasoconstrictors 34. 
    All these results strongly support the hypothesis that increased NO 
production is a major factor in the peripheral arterial vasodilation of 
cirrhosis. Agents promoting nitric oxide production include inflammatory 
cytokines and endotoxin. In that regard, selective intestinal decontamination 
with norfloxacin partially reverses the hyperdynamic circulatory state in 
cirrhotic patients, suggesting a role for the endotoxin-NO pathway 35. Where 
does this endotoxin come from in cirrhosis? First, alcohol is a major cause of 
cirrhosis in Western countries, and alcoholic gastrointestinal mucosal 
damage 36, could potentially facilitate transfer of bacteria into the circulation. 
Second, portosystemic shunting allows gut-derived bacterial endotoxins 
passage to the systemic circulation. Third, cirrhotic patients with portal 
hypertension show intestinal structural abnormalities characterized by 
vascular congestion and edema, which leads to increased intestinal 
permeability to bacterial toxins 37. Fourth, intestinal bacterial overgrowth and 
bacterial translocation are increased in cirrhosis 38. Besides endotoxins, the 
other possible factors stimulating NO production include cytokines such as 
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TNF-α, IL-1, IL-6, and IFN-γ39-41 Among these, TNF-α has been studied the 
most. Lopez-Talavera et al found that anti-TNF-α antibody increases mean 
arterial pressure and systemic vascular resistance, and decreases cardiac 
index and portal pressure 42. In 4-week BDL rats, in parallel with increased 
serum TNF-α, aortic NOS3 expression and serum nitrate/nitrite 
concentrations were increased 43. 
    Although the evidence is strong that the increased NOS activity in 
cirrhosis plays an important role in hyperdynamic circulation in cirrhosis, it 
remains obscure which NOS isoform is involved. The majority of previous 
studies have used a nonspecific NOS inhibitor to diminish NO production. 
However, a recent study used aminoguanidine, a preferential inhibitor of 
NOS2 (inducible NOS), and showed that in vivo, the hyperdynamic 
circulation in portal hypertensive rats is reversed 44. But in another study 
aminoguanidine had no in vitro effect on the hyporeactivity of aortic rings 
from cirrhotic rats 45. We have recently evaluated the activity of the L-
arginine-NO pathway at different levels 43. Although NOS2 mRNA was 
detectable in the cirrhotic aorta, no NOS2 protein was observed in our 
Western blots. It is unclear why the mRNA was not expressed as a protein. It 
might have been degraded or not been transcribed. It is also possible that our 
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method of Western blotting did not allow the detection of small amounts of 
NOS2 protein. 
    A consistent augmentation in the expression of NOS3 mRNA and protein 
levels is observed in cirrhotic rats. Because NOS3 can be upregulated by 
stimuli such as shear stress and mechanical deformation, some have 
suggested that hyperdynamic circulation is the cause rather than the 
consequence of the activation of the NO pathway 31, 46, 47. In addition, there 
may be other reasons for the increased NOS3. Cirrhosis is associated with 
increased levels of estrogens 48,49, and these compounds have been shown to 
upregulate NOS3 activity50. Other factors which may stimulate NOS3 
expression need further investigation. 
     What is the role of another isoform of NOS, neuronal NOS (nNOS or 
NOS1)? Xu and his colleagues have demonstrated that nNOS expression is 
significantly increased in rat cirrhotic aortae 51. Furthermore, a nNOS-
specific inhibitor, 7-nitroindazole (7-NI), significantly decreased the sodium 
and water retention and normalized the hyperdynamic indices such as 
cardiac index, mean arterial pressure, and systemic vascular resistance in 
these rats 51. Biecker et al also showed that nNOS partially compensates for 
the absence of eNOS in producing hyperdynamic circulation in eNOS-gene 
knockout mice 52. These data indicate that the nNOS isoform plays a major 
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pathogenic role in hyperdynamic circulation, and perhaps even in renal salt 
and water retention in cirrhosis. 
    It seems that endocannabinoids and nitric oxide may both play an 
important role in hyperdynamic circulation, but what is the relationship 
between them? The literature remains inconclusive. In a kidney study, 
Deutsch et al found that the vasodilatation of anandamide is NO dependent, 
because the NOS inhibitor L-NAME completely blocked the vasodilatory 
effect of anandamide, similar to a CB1 antagonist 53. However, another study 
showed no effect of L-NAME infusion on the hypotensive effects of 
anandamide 24. 
    Some studies suggest the possible involvement of other humoral 
vasodilators, but a definitive pathogenic role for any of these substances 
remains elusive. This list includes: glucagons 54, prostaglandins 55, GABA56, 
VIP 57, bile acids 58, endotoxin, histamine 59 and adenosine 60. 
  
Central neural mechanisms 
Although most research has focused on the humoral mediators, in 
recent years we and others have shown an important mechanistic role of 
central nervous system (CNS) activation. A decade ago, it was demonstrated 
that primary afferent denervation by capsaicin reversed the hyperdynamic 
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circulation in rats with cirrhosis or portal hypertension due to portal vein 
stenosis (PVS)61. What is the relationship between the CNS and 
hyperdynamic circulation in portal hypertension? Using c-fos, an immediate-
early gene (whose protein product can be detected by immunohistochemistry 
as Fos), as a marker of central neuronal activation,  it was showed that the 
brainstem and hypothalamic cardiovascular-regulatory nuclei are activated at 
the first day after PVS, whereas the hyperdynamic circulation does not start 
up until 3-5 days after PVS. This time sequence suggests that central neural 
activation is the initiating signal in the pathogenesis of hyperdynamic 
circulation. 
    Subsequently, in portal hypertensive rats, when c-fos antisense 
oligonucleotide was microinjected into one of the major cardiovascular-
regulatory brainstem nuclei, the nucleus tractus solitarius (NTS), to block 
local Fos expression. This treatment completely blocked the development of 
the hyperdynamic circulation, i.e., abnormalities in cardiac output, mean 
arterial pressure and systemic vascular resistance were completely 
eliminated 62. In normal control rats, c-fos antisense oligonucleotides had no 
effect62. These results indicate that central neural activation is a sine qua non 
for the development of the hyperdynamic circulation in portal hypertension. 
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    The CNS, as the controller of the circulation, presumably would not 
arbitrarily activate the cardiovascular system without reason. This raises the 
question of what the initiating signal is. Likely, it is somehow related to the 
portal hypertension per se. Moreover, the exact route of signaling from the 
periphery to the CNS remains unclear. The aforementioned capsaicin study 
suggests that primary afferent nerves may be the signaling pathway from the 
periphery to the CNS 61. A subsequent study showed that capsaicin-treated 
BDL rats improve the renal function and do not develop ascites63. Moreover, 
both BDL-cirrhotic and portal hypertensive rats show diminished Fos 
expression in NTS after capsaicin-induced denervation of the afferent nerves 
as neonates63. These observations indicate that intact primary afferent 
innervation is necessary for the central neuronal activation and development 
or maintenance of hyperdynamic circulation. Additionally, sodium retention 
and ascites formation is also dependent on either the presence of 
hyperdynamic circulation or intact afferent innervation, or both. The 
complex relationship between CNS activation, local or neurohormonal 
humoral factor stimulation, and cardiovascular disturbances in 
cirrhosis/portal hypertension continues to be studied in several labs.  
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Cirrhotic Cardiomyopathy  
This syndrome was first described in the late 1960s, although for many 
years, it was mistakenly attributed to latent or subclinical alcoholic 
cardiomyopathy 64-66. However, studies in human and animal models with 
nonalcoholic cirrhosis, dating from the mid-1980s showed a similar pattern 
of increased baseline cardiac output with blunted response to stress 21. The 
clinical features of cirrhotic cardiomyopathy include blunted systolic and 
diastolic contractile responses to stress, in conjunction with evidence of 
ventricular hypertrophy or chamber dilatation and electrophysiological 
abnormalities including prolonged QT interval. Recent studies suggest the 
presence of cirrhotic cardiomyopathy may contribute to the pathogenesis of 
hepatorenal syndrome precipitated by spontaneous bacterial 
peritonitis67,acute heart failure after insertion of transjugular intrahepatic 
portosystemic shunts (TIPS) 68,69, and increased cardiovascular morbidity and 
mortality after liver transplantation70. Therefore this syndrome is more than 
an academic curiosity, but rather an important clinical entity.  
  
Endocannabinoids 
Endocannabinoids are known to have a negative inotropic effect on 
cardiac contractility in both human71 and rats72. The plasma level of an 
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endogenous cannabinoid, anandamide, is known to be increased in     
cirrhosis 23. We recently demonstrated a major role for increased local 
cardiac production of endocannabinoids in cirrhotic cardiomyopathy 73. This 
conclusion is based on the restoration of blunted contractile response of 
isolated left ventricular papillary muscles from BDL-cirrhotic rats after 
preincubation with a CB1 antagonist, AM251. Additionally, 
endocannabinoid reuptake blockers (VDM11 and AM404) enhance the 
relaxant response of cirrhotic papillary muscle to higher frequencies of 
contraction in an AM251-sensitive fashion, suggesting an increase in the 
local production of endocannabinoids acting through CB1 receptors. Other 
in vitro evidence suggests a main neuronal source for the increase in local 
production of endocannabinoids, as these effects were mostly abolished by 
pretreatment with the neurotoxin tetrodotoxin. 
  
β -adrenergic signaling 
Cardiac-adrenergic signaling is one of the main regulators of cardiac 
contractility. Adrenergic receptors increase adenylyl cyclase activity through 
stimulatory G proteins. Increased production of cAMP in turn results in an 
increase in calcium influx and contractile force mainly through activation of 
protein kinase A (PKA). We have previously shown that expression and 
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responsiveness of β-adrenergic receptors74 as well as its post receptor 
signaling pathway is blunted in cardiac tissue of cirrhotic rats. Post receptor 
impairment was found at different levels including content and function of 
stimulatory Gs-proteins 75, uncoupling of the β-adrenoceptor-ligand complex 
from G protein 76, and responsiveness of adenylyl cyclase to stimuli 75,77. 
  
Membrane fluidity 
Biochemical and biophysical properties of the cell membrane 
determines the mobility of membrane-bound protein moieties. This mobility 
is known as membrane fluidity 78, which is shown to be an important factor 
in the function of a number of membrane-bound receptors including β-
adrenergic receptors79.  It was shown that membrane fluidity in 
cardiomyocytes from bile duct-ligated rats is decreased in association with 
an increase in membrane cholesterol content and cholesterol/phospholipid 
ratio 75. Restoration of these abnormalities in vitro results in normalization of 
blunted response of β-adrenergic receptors75. Alterations in membrane 
fluidity may also play a role in abnormal function of other membrane-bound 
components in cirrhotic cardiomyocytes including ion channels. The 
significant decrease in K+ currents through Ca2+-independent transient 
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outward K+ channel and the delayed rectifier current reported by Ward et al 
is an example that requires further investigation80. 
  
Nitric oxide 
Nitric oxide is known to negatively regulate cardiac contractile 
function. It has been shown to be involved in some types of cardiac 
dysfunction including ischemic heart disease 81. Balligand et al have reported 
that non-selective blockade of NOS augments the contractile response of rat 
ventricular myocytes to the β-agonist isoproterenol without affecting the 
baseline contractility 82. Whether this effect is mediated by the inhibition of 
adenylyl cyclase activity by NO 83 or through the second messenger, cyclic 
guanosine monophosphate (cGMP), remains to be elucidated. Possible 
effects of NO on cardiac function in physiological and some 
pathophysiological states were extensively reviewed previously 84, 85. 
    As noted previously, cirrhosis is known to be associated with NO 
overproduction 46. Involvement of NO overproduction in the development of 
cirrhotic cardiomyopathy was first reported in 1996 by Van Obbergh et al in 
the BDL rat. They showed that a nonselective NOS inhibitor, L-NMMA, 
restored the blunted contractile function of isolated heart from cirrhotic rats 
while it had no significant effect in control animals 86. A similar effect was 
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reported in isolated left ventricular papillary muscles of cirrhotic rats. 
Furthermore, it was observed that iNOS and not eNOS mRNA and protein 
expression were significantly increased in the heart of a cirrhotic rat 39. 
Increased levels of cGMP in cirrhotic ventricles and elevated serum and 
cardiac levels of cytokines like TNF-α suggest a cytokine/iNOS/cGMP 
pathway for this effect 39. 
  
Carbon monoxide 
Carbon monoxide (CO) is mainly produced in the body through the 
action of heme oxygenases. These enzymes are responsible for converting 
heme to biliverdin and CO. Like NO, CO activates soluble guanylate cyclase 
resulting in increased levels of cGMP 87,88. Expression of inducible heme 
oxygenase (HO-1) mRNA was increased in the right ventricle in a canine 
model of congestive heart failure 89. We previously reported an increase in 
mRNA and protein expression of HO-1 in left ventricle of bile duct-ligated 
rats, which was associated with an increase in left ventricular cGMP     
levels 90. Furthermore, treatment of cirrhotic heart with an HO inhibitor, zinc 
protoporphyrin IX, restored the elevated cGMP levels 90. These findings 
suggest the involvement of an HO-CO-cGMP pathway in the development 
of cirrhotic cardiomyopathy. 
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Cardiomyopathies 
The cardiomyopathies are a group of diseases that primarily affect the 
heart muscle and are not the result of congenital, acquired valvular, 
hypertensive, coronary arterial or pericardial abnormalities. Two 
fundamental forms of cardiomyopathy are recognized: (1) a primary type, 
consisting of heart muscle disease predominantly involving the myocardium 
and/or of unknown cause; and (2) a secondary type, consisting of myocardial 
disease of known cause or associated with a systemic disease such as 
amyloidosis or chronic alcohol use. In many cases it is not possible to arrive 
at a specific etiologic diagnosis, and thus it is often more desirable to 
classify the cardiomyopathies into one of three morphologic types (dilated, 
restrictive, and hypertrophic) on the basis of differences in their 
pathophysiology and clinical presentation. 
About one in three cases of congestive heart failure is due to dilated 
cardiomyopathy (DCM). LV and/or right ventricular (RV) systolic pump 
function is impaired, leading to progressive cardiac dilatation. The 
electrocardiogram (ECG) often shows sinus tachycardia or atrial fibrillation, 
ventricular arrhythmias, left atrial abnormality, low voltage, diffuse 
nonspecific ST-T-wave abnormalities, and sometimes intraventricular and/or 
AV conduction defects. Echocardiography shows LV dilatation, with 
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normal, minimally thickened, or thinned walls, and systolic dysfunction. 
Circulating levels of brain natriuretic peptide are usually elevated. 
Hypertrophic cardiomyopathy (HCM) is characterized by LV 
hypertrophy, typically of a nondilated chamber, without obvious cause, such 
as hypertension or aortic stenosis. The ubiquitous pathophysiologic 
abnormality is diastolic dysfunction, which can be detected by Doppler 
tissue imaging and results in elevated LV end-diastolic pressures; the latter 
may be present despite a hyperdynamic, nondilated LV. The ECG 
commonly shows LV hypertrophy and widespread deep, broad Q waves. 
The hallmark of the restrictive cardiomyopathies (RCMs) is abnormal 
diastolic function .The ventricular walls are excessively rigid and impede 
ventricular filling. In late stages systolic function is also impaired. 
Myocardial fibrosis, hypertrophy, or infiltration due to a variety of causes is 
responsible. ECG often shows low-voltage, nonspecific ST-T-wave 
abnormalities and various arrhythmias. Echocardiography, reveal 
symmetrically thickened LV walls and normal or slightly reduced 
ventricular volumes and systolic function; the atria are usually dilated. 
Doppler echocardiography typically shows diastolic dysfunction. Cardiac 
catheterization shows a reduced cardiac output, elevation of the RV and LV 
end-diastolic pressures, and a dip-and-plateau configuration of the diastolic 
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portion of the ventricular pressure pulses resembling constrictive 
pericarditis. 
 
Cirrhotic cardiomyopathy 
In the absence of specific diagnostic criteria, the exact prevalence of  
cirrhotic cardiomyopathy remains unclear. At present, cirrhotic 
cardiomyopathy can be defined as the constellation of one or more of these 
following factors74: 
• Normal or increased left ventricular systolic contractility at rest, but 
attenuated systolic or diastolic responses to stress stimuli,  
• Structural or histological changes in cardiac chambers, 
• Electrophysiological abnormalities such as prolonged  
electrocardiographic QT interval,  
• Serum markers suggestive of cardiac stress. 
 
Systolic dysfunction 
Despite the increased or normal cardiac output at rest, under 
physiological stress cirrhotic patients fail to mount an adequate stimulatory 
cardiac response. Gould et al documented in cirrhotic patients that with 
exercise the left ventricular end-diastolic and pulmonary arterial pressures 
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increased with no change in the cardiac index. In other words, cardiac output 
did not increase despite increased ventricular filling pressures, which 
indicates a highly impaired ventricular response91. Similarly Grose et al 
showed that when cirrhotic patients underwent maximal exercise, cardiac 
output increased by only 97%; this is considered inadequate when compared 
to approximately 300% increase in healthy controls92. Similar blunted 
cardiac systolic response to exercise was also demonstrated by Wong et al93; 
moreover patients with ascites showed greater dysfunction than those with 
preascitic cirrhosis.  
The cardiac response to different physiological stimuli, including 
Valsalva’s maneuver, ice-cold skin stimulation, and mental stress was 
investigated by Lunzer et al and found to be inadequate94. Lee and 
colleagues showed an inappropriate decrease in the cardiac output in the 
postprandial state in cirrhotic patients95. Blunted cardiac responsiveness has 
been reported in response to other pharmacological agents. Limas et al 
showed that angiotensin infusion in cirrhotics resulted in an increase in the 
pulmonary wedge pressure, which reflects left ventricular filling pressure, 
without any change in the cardiac output96. Blunted cardiac responsiveness 
has also been documented in response to catecholamine infusions97. 
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Diastolic dysfunction 
            Diastolic dysfunction is thought to be more prevalent in cirrhotic 
patients98. This is manifested by a stiff, noncompliant ventricle that impairs 
diastolic filling. Finucci et al compared the diastolic function in 42 cirrhotic 
patients with 16 healthy controls. The cirrhotic patients had increased left 
ventricular end-diastolic and left atrial volumes, stroke volume, and late 
diastolic flow velocity compared to normal controls; these results indicate an 
impaired left ventricular relaxation in the cirrhotic patients98. A widely-used 
index of diastolic function is the echocardiographic E/A ratio. This is the 
velocity of the diastolic early filling wave (E) divided by the velocity of the 
late (or atrial) filling wave (A). Normally, this ratio is >1. Many studies have 
demonstrated a low E/A in patients with cirrhosis99. 
 
 Structural/histological changes 
Multiple studies were conducted to evaluate the heart mass in patients 
with liver cirrhosis. Most studies did not show any significant structural 
changes in liver cirrhotic patients100. However, some have reported changes 
of left ventricular hypertrophy in both humans and in portal hypertensive 
rats84. Studies evaluating the heart mass using echocardiography reported 
enlarged left atrial volumes with normal ventricular volumes101. Others 
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however, reported increases in both the end-diastolic and end-systolic 
volumes of the left ventricle102. Changes involving the right heart chambers 
are less pronounced and were normal in most studies103. These cardiac 
changes may be related to the hyperdynamic circulation of cirrhosis and 
were correlated with its severity in some studies. The presence of cardiac 
histological changes has been described in several autopsy studies. Findings 
include myocardial hypertrophy, cardiomyocyte edema, fibrosis, nuclear 
vacuolation, and unusual pigmentation103. However, these changes were 
reported from studies dating back at least 50 years in patients suffering from 
alcoholic cirrhosis. Lunseth et al studied the autopsies of 108 patients with 
cirrhosis from all causes (although most were alcoholic) and demonstrated 
the same cellular myocardial abnormalities that were described in earlier 
studies104. Other studies conducted on animal models including some of our 
work on long-term bile duct ligated cirrhotic rats failed to show any 
histological changes by light microscopy105. This discrepancy between the 
histological changes in human and animal studies is probably related to the 
long disease duration in cirrhotic patients versus the much shorter periods 
needed to induce cirrhosis in animal models. 
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 Electrophysiological abnormalities 
          QT prolongation has been described in patients with liver disease and 
is significantly related to the severity of the underlying liver disease106. 
However, significant ventricular arrhythmias and sudden cardiac death 
remain uncommon. The prolonged QT interval is thought to revert to normal 
following improvement in liver function and liver transplantation107. The 
effect of β-adrenergic blockade on the prolonged QT interval in cirrhotic 
patients was also evaluated and was found to reduce the prolonged QT 
interval towards normal108. Henriksen et al examined the temporal relation 
between electrical and mechanical systole in patients with liver cirrhosis and 
in addition to the prolonged QT interval in their study population they also 
showed alteration in the cardiac excitation-contraction temporal 
relationship109. In conclusion the prolonged QT interval is well linked to 
liver disease and is a feature of cirrhotic cardiomyopathy. Its exact 
mechanism and its prognostic significance require further study. 
 
Serum markers 
Cardiac troponin I and the family of natriuretic peptides were noted to 
be elevated in cirrhotic cardiomyopathy, possibly reflecting the underlying 
myocardial strain. Atrial natriuretic peptides (ANP) are released mainly by 
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the atria in response to stretch, and brain or B-type natriuretic peptide (BNP) 
by the ventricles110. Troponin I increases in conditions leading to ventricular 
hypertrophy or dilatation. Pateron et al showed an increased serum troponin 
I level in about 1/3 of cirrhotic patients. Elevated levels correlated with 
decreased ventricular stroke volume index111. In cirrhotic patients, BNP 
levels correlated significantly with septal thickness and end-diastolic left 
ventricular diameter112,113.  These results suggest the potential role of these 
markers for screening patients with cirrhosis for the presence of cirrhotic 
cardiomyopathy, and thereby identifying such patients for further 
investigations. 
 
Echocardiography 
Echocardiography increasingly has become a key component in the 
routine evaluation of patients with suspected or known cardiovascular 
disease. Two-dimensional (2D) echocardiography is able to visualize the 
heart directly in real time using ultrasound, providing instantaneous 
assessment of the myocardium, cardiac chambers, valves, pericardium, and 
great vessels. Doppler echocardiography measures the velocity of moving 
red blood cells and has become a noninvasive alternative to cardiac 
catheterization for assessment of hemodynamics.  
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2D echocardiography is an ideal imaging modality for assessing left 
ventricular (LV) size and function. 2D echocardiography is useful in the 
diagnosis of LV hypertrophy and is the imaging modality of choice for the 
diagnosis of hypertrophic cardiomyopathy. Other chamber sizes are assessed 
by visual analysis, including the left atrium and right-sided chambers. 
Doppler echocardiography uses ultrasound reflecting off moving red 
blood cells to measure the velocity of blood flow across valves, within 
cardiac chambers, and through the great vessels. Normal and abnormal 
blood flow patterns can be assessed noninvasively. Color-flow Doppler 
imaging displays the blood velocities in real time superimposed upon a 2D 
echocardiographic image. Doppler echocardiography allows noninvasive 
evaluation of ventricular diastolic filling. The transmitral velocity curves 
reflect the relative pressure gradients between the left atrium and ventricle 
throughout diastole. They are influenced by the rate of ventricular 
relaxation, the driving force across the valve, and the compliance of the 
ventricle. There is a progression of diastolic dysfunction, which can be 
assessed by Doppler flow velocity curves. In the early phase of diastolic 
dysfunction there is primarily an impairment of LV relaxation, with reduced 
early transmitral flow and a compensatory increase in flow during atrial 
contraction. As disease progresses, and ventricular compliance declines, left 
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atrial pressure rises, resulting in a higher early transmitral velocity and 
shortening of the deceleration of flow in early diastole so that the filling 
pattern becomes normal, termed pseudonormalization. In patients with the 
most severe diastolic dysfunction and further elevation of left atrial pressure, 
early diastolic flow velocity rises further, termed the restrictive filling 
pattern. The addition of analysis of Doppler tissue velocities of annular 
motion provides further information concerning the diastolic properties. 
 The systolic function is evaluated with the following parameters in 
echocardiography. 
• Ejection fraction  
o Simpson’s apical biplane method is recommended as the 
accurate echo measure of LVEF. 
• Fractinal shortening at endocardium and midwall  
• Stress-shortening relations  
• Pressure volume analysis  
The prevalence and extent of systolic dysfunction in cirrhotic patients 
variable.  If present, it is unlikely to manifest itself without a stimulus. 
Stroke volume and contractile indices such as dP/dt (first derivative of 
ventricular pressure generation) typically are normal or even increased at 
rest.  
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Conventional Doppler echocardiography is the method of choice in 
assessment of diastolic function. The peak velocities of LV filling during the 
early rapid (E wave), atrial contraction (A wave) phases, the ratio of the 2 
filling velocities (E/A ratio), E wave deceleration time and the isovolumetric 
relaxation time are recorded at end-expiration for 5 consecutive beats at 
baseline and again during the phase of Valsalva maneuver.  
Diastolic dysfunction represents a decrease in left ventricular filling 
and reduced possibility to maintain stroke volume without a compensatory 
increase of atrial filling pressures. This condition usually precedes the 
development of systolic dysfunction and is the main determinant of heart 
failure. Diastolic dysfunction appears to be more prevalent in patients with 
cirrhotic cardiomyopathy. 
 
Electrocardiogram 
The electrocardiogram is a graphic recording of electric potentials 
generated by the heart. The signals are detected by means of metal 
electrodes attached to the extremities and chest wall and are then amplified 
and recorded by the electrocardiograph. ECG leads actually display the 
instantaneous differences in potential between these electrodes. 
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Electrophysiological changes including prolonged depolarization and 
impaired cardiac excitation-contraction coupling been demonstrated in 
cirrhotic patients. Repolarization prolongation manifested by a prolonged 
QT interval (more than 440 msec) on the electrocardiogram is found in 30–
50% of patients with cirrhosis.  Severity of liver disease seems to be 
correlated to the degree of QT prolongation. These changes disappear after 
liver transplantation in most patients. 
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AIM OF THE STUDY 
 
1. To study the cardiac dysfunction in cases diagnosed with cirrhosis of 
liver of nonalcoholic etiology 
 
2. To study the conduction disturbances in cases diagnosed with 
cirrhosis of liver of nonalcoholic etiology 
 
3. To assess the relationship between the severity of cirrhosis and the 
presence of cirrhotic cardiomyopathy 
 
4.  To assess the relationship between ascites and the presence of 
cirrhotic cardiomyopathy 
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MATERIALS AND METHODS 
                           Patients  included   in  the  study  were  recruited  from  the  
Department  of  Digestive  Health  and  Diseases,  Government  Peripheral  
hospital,  Anna Nagar, Chennai. The study period was  from  July 2006  to  
April 2009. 
Inclusion criteria 
                          Consecutive patients diagnosed to have cirrhosis of 
nonalcoholic etiology formed  the study  group.  
 
Exclusion criteria 
Cases with the following features were excluded from the study – 
• Cases who are alcoholics  
• Cases with severe ascites  
• Cases who have coronary artery disease  
• Cases who have risk factors for cardiomyopathy other than cirrhosis  
• Cases with history of recent bleed  
• Cases with severe anemia 
• Cases who are hypertensive 
• Cases who are diabetics 
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                   Investigations done include complete blood count, liver function 
test, ultrasound scan of the abdomen along with Doppler scan, viral markers, 
ascitic fluid analysis, liver biopsy, electrocardiography, and 
echocardiography. The parameters that were assessed in echocardiography 
are E/A ratio, end diastolic volume (EDV), end systolic volume (ESV), 
ejection fraction. 
QTc interval more than 440 msec and E/A ratio less than 1 were 
considered diagnostic of cirrhotic cardiomyopathy in this study. End 
diastolic volume of 90, end systolic value of 38 and ejection fraction of 60% 
were considered mean of the normal values while doing statistical analysis. 
                           The statistical analysis was done using SSPS software 
version 15.  Univariate and multivariate analysis were done with Chi Square 
test. P value of < 0.05 was found to be significant. Percentage calculation 
was done whenever appropriate. 
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RESULTS 
The total number of cases included in this study was 30. Of these, 
there were 22 females and 8 males.  
 
Sex distribution 
Sex Frequency Percentage 
Female 22 73.33 
Male 8 26.67 
Total 30 100.00 
 
Of the 30 cases included in this study 10 patients were below 40 years 
of age, 11 cases were between 40 and 50 years of age and 9 cases were 
above 50 years of age. 
 
Age distribution 
Age group in years Frequency Percentage 
Below 40 years 10 33.33 
40-50 years 11 36.67 
Above 50 years 9 30.00 
Total 30 100.00 
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In 12 cases, cirrhosis was due to hepatic B viral infection, 1 due to 
hepatitis C, 1 due to primary biliary cirrhosis and in 16 patients it is 
idiopathic. 
 
Etiology 
Etiology Frequency Percentage 
Hepatitis B virus 12 40.00 
Hepatitis C virus 1 3.3% 
Primary Biliary Cirrhosis 1 3.3% 
Idiopathic 16 53.3% 
Total 30 100 
 
 
 
Clinical findings 
Of the 30 cases included in the study, 24 cases had ascites (80%). 25 
cases had varices (83.33%). 20 cases (66.77%) had Class A Child Turcotte 
Pugh Score. 10 cases (33.33%) had Class B Child Turcotte Pugh Score. 
There were no cases which belonged to Class C of CTP scoring who had 
cirrhosis. 
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Child Turcotte Pugh Class 
CTP Class Frequency Percentage 
Class A 20 66.67 
Class B 10 33.33 
Total 30 100.00 
 
 
 
Ascites 
Ascites Frequency Percentage 
Present 24 80.00 
Absent 6 20.00 
Total 30 100.00 
 
 
Varices 
Varices Frequency Percentage 
Present 25 83.33 
Absent 5 16.67 
Total 30 100.00 
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Conduction disturbances 
Out of the 30 cases who were included in the study, 16 patients had 
QTc interval of more than 440 msec. Of these 16 patients 11 were males and 
5 were female patients. 
 
QTc interval 
QTC value Frequency Percentage 
Above 440 msec 16 53.33 
Below 440 msec 14 46.67 
Total 30 100.00 
 
QTc interval above 440 msec and sex distribution 
Sex Frequency Percentage 
Males 11 68.75 
Females 5 31.25 
Total 16 100.00 
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Left ventricular dysfunction 
Out of the 30 cases, the ratio of early diastolic and late diastolic filling 
velocity (E/A ratio) was less than 1 in 25 cases. Of these 25 cases 19 were 
females and 6 were males. 
E/A ratio 
Value Frequency Percentage 
Below 1 25 83.33 
Above 1 5 16.67 
Total 30 100.00 
 
E/A ratio less than 1 and sex distribution 
Sex Frequency Percentage 
Males 6 24.00 
Females 19 76.00 
Total 25 100.00 
 
Out of the 30 cases included in this study 26 patients had features 
cirrhotic cardiomyopathy. These cases had a prolonged QTc interval of more 
than 440 msec or an E/A ratio of less than 1.  Of these 26 cases, 8 were 
males and 18 were females. 
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Cirrhotic cardiomyopathy 
 Frequency Percentage 
Present 26 86.67 
Absent 4 13.33 
Total 30 100.00 
 
Cirrhotic cardiomyopathy   and sex distribution 
Sex Frequency Percentage 
Males 8 30.00 
Females 18 70.00 
Total 26 100.00 
 
Of the 30 patients included in this study, 14 patients had end diastolic 
volume above 90. 3 patients had end systolic volume above 38. 29 patients 
had ejection fraction above 60%. 
End diastolic volume 
End diastolic volume Frequency Percentage 
Above 90 14 46.67 
Below 90 16 53.33 
Total 30 100.00 
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End systolic volume 
End systolic volume Frequency Percentage 
Above 38 3 10.00 
Below 38 27 90.00 
Total 30 100.00 
 
Ejection fraction 
Ejection fraction Frequency Percentage 
Above 60 29 96.67 
Below 60 1 3.33 
Total 30 100.00 
 
Statistical analysis 
Out of the 30 cases, 26 showed features of cirrhotic cardiomyopathy. 
20 patients had Class A Child Turcotte Pugh score. 10 patients had Class B 
Child Turcotte Pugh score. 16 patients with cirrhotic cardiomyopathy had 
Class A Child Turcotte Pugh score. 10 patients with cirrhotic 
cardiomyopathy had Class B Child Turcotte Pugh score. 4 patients with 
Class A Child Turcotte Pugh score did not have cirrhotic cardiomyopathy. 
The ‘p’ value of this association between Child Turcotte Pugh score and 
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cirrhotic cardiomyopathy is 0.128 and it is not significant. This implies that 
cirrhotic cardiomyopathy is not influenced by the class of Child Turcotte 
Pugh score. 
 Cardiomyopathy 
present 
Cardiomyopathy 
absent 
Total 
Class A CTP score 16 (80%) 4 (20%) 20 (66.7%) 
Class B CTP score 10 (100%)  10 (33.3%) 
Total 26 (86.7%) 4 (13.3%) 30 (100%) 
 P value = 0.336
 
 Class A CTP score Class B CTP score Total 
Cirrhotic 
cardiomyopathy 
Present 
16 (61.5%) 10 (38.5%) 26 (86.7%) 
Cirrhotic 
cardiomyopathy 
Absent 
4 (100%)  4 (13.3%) 
 P value = 0.128
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24 of the 30 cases had ascites. Of the 26 cases that had cirrhotic 
cardiomyopathy 24 cases had ascites. All the cases that had ascites showed 
features of cirrhotic cardiomyopathy. 2 cases without ascites also showed 
features of cirrhotic cardiomyopathy. 4 of the 30 cases did not show features 
of cirrhotic cardiomyopathy. All these 4 cases did not have ascites. The ‘p’ 
value of the association of ascites and cirrhotic cardiomyopathy is 0.0002 
and it is significant. This implies presence of ascites is a significant finding 
in  cases who have cirrhotic cardiomyopathy.  
 
 Cardiomyopathy 
present 
Cardiomyopathy 
absent 
Total 
 
Ascites Present 
 
24 (100%) 
  
24 (80%) 
 
Ascites Absent 
 
2 (33.3%) 
 
4 (67.7%) 
 
6 (20%) 
 
Total 
 
26( 86.7%) 
 
4 (13.3%) 
 
30 (100%) 
  
P value = 0.0002 
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 Ascites Present Ascites absent Total 
Cirrhotic 
cardiomyopathy 
Present 
24 (92.3%) 2 (7.7%) 26 (86.7%) 
Cirrhotic 
cardiomyopathy 
Absent 
 4 (100%) 4 (13.3%) 
  
P value = 0.0002 
 
 
25 of the 30 cases had varices. Of the 26 cases that had cirrhotic 
cardiomyopathy, 21 had varices. 4 cases with varices did not have cirrhotic 
cardiomyopathy. 5 cases with cirrhotic cardiomyopathy did not have varices. 
4 cases did not have cardiomyopathy. All these 4 cases had varices. The ‘p’ 
value of the association between cirrhotic cardiomyopathy and varices is 
0.336 and it is not significant. This implies presence of varices is not a 
significant finding in cases that have cirrhotic cardiomyopathy.  
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 Cardiomyopathy 
present 
Cardiomyopathy 
absent 
Total 
Varices Present 21 (84%) 4 (16%) 25 (83.3%) 
Varices Absent 5 (100%)  5 (16.7%) 
Total 26(86.7%) 4 (13.3%) 30 (100%) 
 P value = 0.336 
 
 Varices Present Varices absent Total 
Cirrhotic 
cardiomyopathy 
Present 
21 (80.8%) 5 (19.2%) 26 (86.7%) 
Cirrhotic 
cardiomyopathy 
Absent 
4 (100%)  4 (13.3%) 
 P value = 0.336 
 
The QTc interval was more than 440 msec in 11 females  and 5 males. 
It was below 440 msec in 11 females and 3 males. 68% of those who had 
QTc above 440 msec were females. Similarly 78% of those who had QTc 
below 440 msec were females. 50% of the 22 females had QTc above 440 
 48
msec. 62.5 of the 8 males had QTc above 440 msec. These associations have 
a ‘p’ value of 0.543 which is not significant. This implies prolongation of 
QTc interval is not a significant finding in patients who are cirrhotics. 
Similarly the prolongation of QTc interval is not influenced by sex. 
 
Sex QTc above 440 msec QTc above 440 msec Total 
Female 11 (50%) 11 (50%) 22 (73.3%) 
Male 5 (62.5%) 3 (37.5%) 8 (26.7%) 
Total 16 (53.3%) 14 (46.7%) 30 (100%) 
 P value = 0.543 
 
 Female Male Total 
QTc interval 
Above 440 msec 
11 (68.8%)  5 (31.2%) 16 (53.3%) 
QTc interval 
Below 440 msec 
11 (78.6%) 3 (21.4%) 14 (46.7%) 
 P value = 0.543 
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Out of the 30 patients, 26 showed features of cirrhotic 
cardiomyopathy.  
14 patients had end diastolic volume above 90. 16 patients had EDV 
below 90. 12 patients with diastolic dysfunction had EDV above 90. 14 
patients with diastolic dysfunction had EDV below 90. 2 patients with EDV 
above 90 did not have diastolic dysfunction.  
The ‘p’ value of this association between EDV and diastolic 
dysfunction is 0.885 and it is not significant.  
This implies that abnormality of EDV is not a significant feature of 
cirrhotic cardiomyopathy. 
 
 Diastolic dysfunction 
Present 
Diastolic dysfunction 
Absent 
Total 
EDV > 90 12 (85.7%) 2 (14.3%) 14 (46.7%) 
EDV < 90 14 (87.5%) 2 (12.5%) 16 (53.3%) 
Total 26 (86.7%) 4 (13.3%) 30 (100%) 
 P=0.885 
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 EDV >  90 EDV < 90 Total 
Diastolic dysfunction  present 12 (46.2%) 14 (53.8%) 26 (86.7%) 
Diastolic dysfunction absent 2 (50%) 2 (50%) 4 (13.3%) 
P value = 0.885
 
3 cases had end systolic volume above 38. 27 cases had ESV below 
38. 2 cases with diastolic dysfunction had ESV above 90. 22 cases with 
diastolic dysfunction had ESV below 38.  1 case with ESV above 38 did not 
have diastolic dysfunction. 3 cases without diastolic dysfunction had ESV 
below 38.  The ‘p’ value of this association between ESV and diastolic 
dysfunction is 0.282 and it is not significant. This implies that abnormality 
of ESV is not a significant feature of cirrhotic cardiomyopathy. 
 
 Diastolic dysfunction  
present 
Diastolic dysfunction 
Absent 
Total 
ESV > 38 2 (66.7%) 1 (33.3%) 3 (10%) 
ESV < 38 24 (88.9%) 3 (11.1%) 27 (90%) 
Total 26 (86.7%) 4 (13.3%) 30 (100%) 
P value = 0.282
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 ESV > 38 ESV < 38 Total 
Diastolic dysfunction  present 2 (7.7%) 24 (92.3%) 26 (86.7%) 
Diastolic dysfunction absent 1 (25%) 3 (75%) 4 (100%) 
P value = 0.282
 
 29 cases had ejection above 60. 3 patients had EF below 60. 25 
patients with cirrhotic cardiomyopathy had EF above 60. 1 case with 
diastolic dysfunction had EF below 60.  4 patients with EF above 60 did not 
have diastolic dysfunction. The ‘p’ value of this association between EF and 
diastolic dysfunction is 0.689 and it is not significant. This implies that 
abnormality of EF is not a significant feature of cirrhotic cardiomyopathy. 
 
 Diastolic dysfunction  
present 
Diastolic dysfunction 
Absent 
Total 
EF > 60 25 (86.2%) 4 (13.8%) 29 (96.7%) 
EF < 60 1 (100%)  1 (3.3%) 
Total 26 (86.7%) 4 (13.3%) 30 (100%) 
P value = 0.689
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 EF > 60 EF < 60 Total 
Diastolic dysfunction  present 25 (96.2%) 1 (3.8%) 26 (86.7%) 
Diastolic dysfunction absent 4 (100%)  4 (13.3%) 
P value = 0.689
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DISCUSSION 
  In this study 12 cases had cirrhosis due to HBV infection, 1 due to 
HCV infection, 1 due to primary biliary cirrhosis and in 16 it was idiopathic. 
Features of cirrhotic cardiomyopathy were present in 26 out of the 30 cases. 
Cirrhotic cardiomyopathy was found in patients with all the etiologies. In a 
study done by Torregrosa M et al114, it was found that the cardiac changes in 
cirrhosis are independent of the etiology of cirrhosis. Lunzer et al115 in their 
study found that cardiac dysfunction in cirrhotics did not correlate with the 
etiology of the cirrhosis. Our study also showed that the presence of cirrhotic 
cardiomyopathy was independent of the etiology. 
 
Of the 30 cases included in this study, 22 were females and 8 were 
males. Of the 22 females 18 had features of cirrhotic cardiomyopathy. All 
the eight males had features of cirrhotic cardiomyopathy. This study showed 
there is no significance between sex distribution and that features of cirrhotic 
cardiomyopathy is present in most of the cirrhotics. Liu et al13 in their study 
found that some amount of diastolic dysfunction is seen in almost all 
cirrhotics. 
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In our study 33.3% of the cases were below 40 years and 66.7% above 
40 years.  The four patients who were not showing features of cirrhotic 
cardiomyopathy were below 40 years. It was statistically significant and 
implied that the presence of cirrhotic cardiomyopathy is influenced by age 
and is more prevalent in older individuals. Rabie et al116 in their study found 
that diastolic dysfunction seen in cirrhosis is associated with older age which 
is similar to the finding of our study. 
80% of the cases had ascites at presentation. All the cases who 
presented with ascites had features of cirrhotic cardiomyopathy. 33.33% of 
the cases who did not have ascites had features of cirrhotic cardiomyopathy. 
On the other hand 92.3% of the patients with cirrhotic cardiomyopathy had 
ascites and 7.7% did not have ascites.  This shows that presence of ascites 
correlates significantly with the presence of cirrhotic cardiomyopathy 
(‘p’=0.0002). Wong et al117 have found that diastolic dysfunction may be a 
significant factor in the development of heart failure, may precede systolic 
dysfunction in patients with cirrhosis, and may play a part in the 
pathogenesis of sodium fluid retention in cirrhosis and thus related to 
ascites. Pozzi et al118 in their study have found that irrespective of ascites 
and cause, advanced cirrhosis is associated with left ventricle diastolic 
dysfunction. But in our study ascites was a significant feature of all cases 
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with diastolic dysfunction. Lee et al13 found that once cirrhosis has advanced 
to a moderate stage with the development of ascites some degree of diastolic 
dysfunction is always present. 
66.7% of the cases had CTP Class A cirrhosis. 33.3% of the cases had 
Class B cirrhosis. 80% of Class A had features of cirrhotic cardiomyopathy. 
All the cases with Class B had features of cirrhotic cardiomyopathy. 61.5% 
of the cases with cirrhotic cardiomyopathy had Class A cirrhosis. 38.5% had 
Class B cirrhosis. 20% of Class A and 13.3% of Class B cirrhosis did not 
have features of cirrhotic cardiomyopathy. The severity of cirrhosis as based 
on CTP does not correlate with the presence of cirrhotic cardiomyopathy 
(‘p’= 0.336). Bernardi et al119 in their found that the frequency of cardiac 
dysfunction was dependent on the severity of cirrhosis as assessed by Child 
Turcotte Pugh score. Similar observation was done by Rabie et al116 in their 
study on diastolic dysfunction in cirrhotics. But in our study no such 
correlation was found. 
 55.3% of the cases had QTc interval above 440 msec. Of these 68.8% 
were females and the rest males. Of the 22 females included in the study 
50% had QTc interval above 440 msec. Of the 8 males included in the study 
62.5% had prolonged QTc interval. These findings show that sex is not a 
factor in influencing the prolongation of QTc interval in cirrhotics (‘p’= 
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0.543). Bader Faiyaz Zuberi et al120 in their study conducted in cirrhotics 
from Pakistan have found that QTc were significantly higher in cirrhotic 
patients as compared with non-cirrhotic controls. Similarly Bernardi et al119 
found that QTc interval was significantly prolonged in cirrhotic patients 
when compared with healthy individuals. Lehman121 found that prolonged 
QTc interval was seen more in female cirrhotics. But this study did not show 
any such correlation. 
46.7% of the cases had end diastolic volume above 90. 85.7% of the 
cases with EDV above 90 had E/A ratio below 1. 87.5% of cases with EDV 
below 90 also had E/A ratio below 1. 46.2% of the cases with E/A ratio 
below 1 had EDV above 90. 53.8% of the cases with E/A ratio below 1 had 
EDV below 90. These findings indicate that end diastolic volume is not 
significant indicator of diastolic dysfunction (‘p’ = 0.885). Alexander Jacob 
et al122 in their study done in Asian population with cirrhosis have found that 
end diastolic volume is not statistically significant in them. Kelbaek et al123 
in their study have found that the left ventricular end diastolic volume is 
normal in cirrhotics. Rectar et al124 found that the size of the left ventricle 
was normal in cirrhotics. Laffi et al125 in their study have found that left 
ventricular end diastolic volume is increased in cirrhotic patients. 
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10% of the cases had end systolic volume above 38. 66.7% of the 
cases with ESV above 38 had E/A ratio below 1. 88.9% of the cases with 
ESV below 38 also had E/A ratio below 1. 7.7% of the cases with E/A ratio 
below 1 had ESV above 38. 25% of the cases with E/A ratio above 1 also 
had ESV above 38. These findings indicate that end systolic volume is not 
significant indicator of cardiac dysfunction (‘p’ = 0.282). Alexander Jacob et 
al in their study done in Asian population with cirrhosis have found that end 
systolic volume is not statistically significant in them. Kelbek et al in their 
study have found that the left ventricular end systolic volume is normal in 
cirrhotics. Rectar et al found that the size of the left ventricle was normal in 
cirrhotics. Laffi et al in their study have found that left ventricular end 
systolic volume is increased in cirrhotic patients. 
 
96.7% of the cases had ejection fraction above 60%. 86.2% of the 
cases with EF above 60 had E/A ratio below 1. 96.2% of the cases with E/A 
below 1 had EF above 60. All the cases that had E/A ratio above 1 also had 
EF above 60. These findings indicate that ejection fraction is not significant 
indicator of cardiac dysfunction (‘p’ = 0.689). Alexander Jacob et al in their 
study done in Asian population with cirrhosis have found that ejection 
fraction is not statistically significant in them. 
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CONCLUSION 
• Cirrhotic patients with non alcoholic etiology do have evidence of 
cirrhotic cardiomyopathy. They have features in the form of diastolic 
dysfunction and prolonged QTc interval. Diastolic dysfunction is 
manifested as E/A ratio less than 1. 
• The presence of cirrhotic cardiomyopathy was independent of the 
etiology.  
• Some degree of diastolic dysfunction is seen in almost all cirrhotics. 
• Diastolic dysfunction seen in cirrhosis is associated with older age. 
• Ascites is a significant feature of all cases with diastolic dysfunction. 
• The severity of cirrhosis does not correlate with the presence of 
diastolic dysfunction 
• Prolongation of QTc interval is influenced by the sex of the cirrhotic 
individuals 
• Ventricular end diastolic volume, end systolic volume and ejection 
fraction are not significantly affected in cirrhotic individuals. 
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